Abstract
The treatment of hematologic malignancies is moving towards risk-stratified directed therapy, whereby treatment is based on the disease's biological characteristics and response to treatment. We investigated whether BCL2 and BCL6 status could add to the prognostic information yielded by an interim positron emission tomography (PET) scan in the ability to predict outcome. Negative interim scans and BCL2-negative status correlated with continuing remission (p<0.005) at a median follow up of 24 months.
| Original language | English |
|---|---|
| Journal | Haematologica |
| Volume | 90 |
| Issue number | 12 |
| Pages (from-to) | 1711-3 |
| Number of pages | 3 |
| ISSN | 0390-6078 |
| Publication status | Published - Dec 2005 |
Keywords
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Biomarkers, Tumor/analysis
- Biopsy
- DNA-Binding Proteins/analysis
- Disease Progression
- Follow-Up Studies
- Humans
- Lymphoma, Large B-Cell, Diffuse/chemistry
- Positron-Emission Tomography
- Prognosis
- Proto-Oncogene Proteins c-bcl-2/analysis
- Proto-Oncogene Proteins c-bcl-6
- Remission Induction
- Retrospective Studies
- Treatment Outcome